Highest-materiality recent filing
Healthpeak raises FY 2026 guidance; Q1 FFO as adj $0.45, Janus Living IPO nets $880M
Net income $0.28, Nareit FFO $0.42, FFO as adjusted $0.45 per share for Q1 2026.
Healthpeak shareholders elect all 9 directors, approve say-on-pay, ratify auditor
All nine director nominees elected with at least 96.4% of votes cast; board size reduced to nine.
Healthpeak OP secures $400M delayed draw term loan; total credit facility capacity raised to $2.0B
Healthpeak OP obtained $400M senior unsecured delayed draw term loan commitments with a 5-year maturity.
Healthpeak CEO Scott Brinker to present at Citi 2026 Global Property CEO Conference on March 3
Scott Brinker, President and CEO, presents at Citi 2026 Global Property CEO Conference on March 3, 2026, at 9:35 a.m. ET.
Healthpeak forms Janus Living for senior housing IPO; Q4 FFO $0.47, same-store NOI +3.9%
Planned IPO of Janus Living, a dedicated senior housing REIT, to unlock value; Healthpeak to retain ownership stake.
Healthpeak Q3 net loss $0.17/sh; AFFO $0.42; same-store NOI +0.9%
GAAP net loss of $117M ($0.17 diluted) vs income $85.7M ($0.12) in Q3 2024.
Healthpeak OP completes $500M offering of 4.750% senior notes due 2033
Aggregate principal $500M, 4.750% notes due Jan 15, 2033, semi-annual interest from Jan 15, 2026.
Healthpeak Prices $500M 4.750% Senior Notes due 2033 to Repay Commercial Paper
Issued $500M of 4.750% senior unsecured notes due 2033 at 99.178% of par.
Healthpeak updates federal income tax considerations in registration statement
Exhibit 99.1 supersedes prior U.S. federal income tax discussion in Feb 5, 2025 prospectus.
Healthpeak Q2 net income $0.05 EPS vs $0.21 YoY; FFO as Adj. $0.46 vs $0.45
Net income $0.05 diluted EPS vs $0.21 YoY; FFO as Adjusted $0.46 vs $0.45, AFFO $0.44 vs $0.40.
Healthpeak VP Chair John Thomas to speak at BofA Healthcare Conference May 14
John Thomas, Vice Chair of Healthpeak, to participate in a panel at BofA Securities 2025 Healthcare Conference on May 14, 2025 at 8:00 a.m. PT.
Healthpeak Properties stockholders approve employee stock purchase plan at 2025 annual meeting
ESPP approved by 98.4% of votes cast; employees may purchase shares at 85% discount via payroll deductions.
Healthpeak appoints Kelvin Moses as CFO; led $5B Physicians Realty integration
Kelvin O. Moses appointed CFO effective April 24, 2025, succeeding under succession plan.
Healthpeak Q1 net income $0.06/sh, FFO as Adjusted $0.46; same-store NOI up 7%
Net income $42.4M ($0.06 diluted EPS); Nareit FFO $0.45/sh, FFO as Adjusted $0.46/sh, AFFO $0.43/sh.
Healthpeak CFO Peter Scott resigns; to lead Healthcare Realty Trust as CEO
Peter Scott resigned as CFO on April 2, 2025; not due to any disagreement with the company.
Healthpeak CEO Scott Brinker to present at Citi 2025 Global Property CEO Conference
CEO Scott Brinker to present at Citi 2025 Global Property CEO Conference on March 3, 2025 at 1:30 p.m. ET.
Healthpeak OP closes $500M senior notes offering at 5.375% due 2035
Issued $500M aggregate principal of 5.375% senior notes due February 15, 2035.
Healthpeak prices $500M 5.375% senior notes due 2035; net proceeds ~$494.5M
Offering of $500M aggregate principal amount of 5.375% senior unsecured notes maturing in 2035.
COO Thomas Klaritch to retire; steps down March 1, 2025, employment ends Sept 30, 2025
Thomas Klaritch, COO and leader of outpatient medical segment, will retire effective March 1, 2025.
Healthpeak Q4 net income $0.01/sh; dividend raised 1.7% to $0.305; leadership shifts
Q4 net income $0.01/sh; Nareit FFO $0.44; FFO as Adj $0.46; AFFO $0.40.
Healthpeak extends $3B revolver to Jan 2029; SOFR+77.5 bps pricing
Credit facility extended to January 2029 with two six-month extension options.
Healthpeak raises FY2024 guidance at REITworld conference; specific increases undisclosed in filing
Company presented at Nareit's REITworld 2024 on Nov 18, 2024, increasing certain full-year 2024 guidance ranges.
Healthpeak furnishes November 2024 investor presentation with no material new disclosures
Investor presentation furnished as Exhibit 99.1; no specific financial results or guidance provided.
Healthpeak Q3 FFO as Adjusted $0.45; raises FY guidance; lab leasing 733K sq ft
Net income $0.12/share; FFO as Adjusted $0.45; AFFO $0.41; same-store cash NOI growth 4.1%.
Healthpeak reports Q2 EPS $0.21, raises FY guidance, $1.2B YTD dispositions
Net income diluted $0.21/share in Q2 2024 vs $0.09 in Q2 2023; Nareit FFO $0.44, FFO as Adjusted $0.45, AFFO $0.39.
Healthpeak merger pro forma shows 2023 diluted EPS $0.22, Q1 2024 loss $0.03
Pro forma 2023 revenue $2.77B, net income $152.7M; diluted EPS $0.22.
Healthpeak directors Garvey and Henry retire; board shrinks to 11; say-on-pay and auditor ratified
Christine Garvey and David Henry retired from the Board effective before the 2024 annual meeting per term limit policy.
Healthpeak Q1 FFO as Adjusted $0.45 beats; raises full-year guidance midpoint by $0.02
Q1 net income $0.01/sh; FFO as Adj $0.45 (vs $0.42 YoY); AFFO $0.41 (vs $0.38).
Healthpeak files prospectus supplement for resale of up to 6.55M shares upon exchange of units
Registration covers resale of up to 6,546,873 shares issuable upon exchange of 6,546,913.828 non-managing member units of DOC DR, LLC.
Healthpeak establishes $1.5B at-the-market equity offering program
Amendment to ATM equity sales agreement executed March 11, 2024, adding up to $1.5B in common stock issuance capacity.
Healthpeak closes Physicians Realty Trust acquisition; ticker to change to DOC
Each Physicians Realty Trust common share converted into 0.674 Healthpeak shares.
Healthpeak files investor presentation for Citi 2024 Global Property CEO Conference
Furnished under Regulation FD for use at Citi conference and investor meetings on March 1, 2024.
Healthpeak receives required consents to amend DOC notes indentures for merger
Consents obtained from majority holders of $400M 4.300% notes due 2027, $350M 3.950% notes due 2028, $500M 2.625% notes due 2031.
Physicians Realty Trust FY2023 audited financials filed; net income $43.8M, diluted EPS $0.17
Total revenues $543.5M in 2023, up from $526.6M in 2022; net income fell to $43.8M from $110.0M.
Healthpeak stockholders and Physicians Realty shareholders approve merger; close expected March 1
Healthpeak stockholders approved stock issuance with 456.7M for, 11.9M against.
Healthpeak files new shelf registration statement and 11 prospectus supplements
Filed automatic shelf registration on Feb 8, 2024, replacing prior registration statement.
Healthpeak starts consent solicitation to amend $1.25B DOC notes; offers guarantee and $1/$1,000
Covers three series: 4.300% notes due 2027 ($400M), 3.950% due 2028 ($350M), 2.625% due 2031 ($500M).
Healthpeak Q4 FFO as Adj $0.46/share; Same-store NOI +3.6%; new $236M lab JV
Q4 net income $0.13/share, Nareit FFO $0.48, FFO as Adj $0.46, AFFO $0.36; FY23 net income $0.56, Nareit FFO $1.79, FFO as Adj $1.78, AFFO $1.53.
Physicians Realty Trust provides preliminary Q4 & FY 2023 estimates ahead of Healthpeak merger
Preliminary Q4 net income $4M-$11M ($0.02-$0.04 EPS); FFO per share $0.22-$0.24.
On April 24, 2025, the Board of Directors of Healthpeak Properties, Inc. (the “Company”) appointed Kelvin O. Moses as the Company’s Chief Financial Officer and principal financial officer, effective immediately, pursuant to the Company’s succession plan.
On April 2, 2025, Peter A. Scott informed Healthpeak Properties, Inc. (the “Company”) of his resignation from his position as Chief Financial Officer of the Company.
Thomas Klaritch, currently the Company’s Chief Operating Officer, will retire from the Company.
Christine N. Garvey and David B. Henry retired from the Board of Directors (the “Board”) of Healthpeak Properties, Inc. (the “Company”) effective immediately prior to the 2024 annual meeting of stockholders held on April 25, 2024 (the “Annual Meeting”).
Christine N. Garvey and David B. Henry retired from the Board of Directors (the “Board”) of Healthpeak Properties, Inc. (the “Company”) effective immediately prior to the 2024 annual meeting of stockholders held on April 25, 2024 (the “Annual Meeting”).
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
Max materiality 0.95 · Median 0.55 · Most common event other_material